AR057433A1 - Compuestos quimicos derivados de piridopirimidina, un metodo para su preparacion y composicion farmaceutica - Google Patents
Compuestos quimicos derivados de piridopirimidina, un metodo para su preparacion y composicion farmaceuticaInfo
- Publication number
- AR057433A1 AR057433A1 ARP060102882A ARP060102882A AR057433A1 AR 057433 A1 AR057433 A1 AR 057433A1 AR P060102882 A ARP060102882 A AR P060102882A AR P060102882 A ARP060102882 A AR P060102882A AR 057433 A1 AR057433 A1 AR 057433A1
- Authority
- AR
- Argentina
- Prior art keywords
- 4alkyl
- alkyl
- optionally substituted
- alkoxy
- heteroaryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 24
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- -1 cyano, hydroxy Chemical group 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical group 0.000 abstract 7
- 125000001072 heteroaryl group Chemical group 0.000 abstract 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 210000002460 smooth muscle Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto derivado de piridopirimidina, un proceso para preparar dicho compuesto; y una composicion farmacéutica en base al compuesto. Estos compuestos son utiles para tratar dolencias de las vías respiratorias, la musculatura lisa y ejercen actividad benéfica sobre la actividad de los nervios pulmonares. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1), en donde: A es N o CA1; E es N o CE1; T es C(O) o S(O)2; X es C o S; W es (CH2)n; Y es (CH2)p; n y p son, en forma independiente 0 o 1; L es CH o N; cuando L es CH entonces J es NH; y cuando L es N entonces J está ausente y T se une directamente a L; R1 es arilo o heteroarilo, cada uno de los cuales está opcionalmente sustituido con halogeno, ciano, hidroxi, alquilo C1-4, alcoxi C1-4, CF3, OCF3, alquiltio C1-4, S(O)alquiloC1-4, S(O)2alquiloC1-4 o C(O)2alquiloC1-4; R2 es alquilo C1-6 (opcionalmente sustituido por hidroxilo, alcoxi C1-6, heterociclilo (opcionalmente sustituido por alquilo C1-6), arilo, heteroarilo, cicloalquilo C3-7, CO2H, CO2alquiloC1-6 o NHC(O)R3), alcoxi C1-6, cicloalquilo C3-6 (opcionalmente sustituido por hidroxilo o alquilo C1-6), heterociclilo (opcionalmente sustituido por alquilo C1-6), arilo o heteroarilo; R3 es alquilo C1-6 o fenilo; las mencionadas porciones fenilo, arilo y heteroarilo de R2 y R3 opcionalmente se sustituyen en forma independiente con:: halogeno, ciano, nitro, hidroxi, S(O)qR4, OC(O)NR5R6, NR7R8, NR9C(O)R10, NR11C(O)NR12R13, S(O)2NR14R15, NR16S(O)2R17, C(O)NR18R19, C(O)R20, CO2R21, NR22CO2R23, alquilo C1-6, hidroxialquilo C1-6, haloalquilo C1-6, alcoxi-C1-6-alquiloC1-6, di-alquilaminoC1-6-alquiloC1-6, alcoxi C1-6, haloalcoxi C1-6, alcoxiC1-6-alcoxiC1-6, alquiltio C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-10 (en sí opcionalmente sustituido por alquilo C1-4 o oxo), metilendioxi, difluorometilendioxi, fenilo, fenil-alquiloC1-4, fenoxi, feniltio, fenil-alcoxiC1-4, heteroarilo, heteroaril-alquiloC1-4, heteroariloxi o heteroaril-alcoxiC1-4; en donde cualquiera de las porciones fenilo y heteroarilo inmediatamente precedentes opcionalmente se sustituyen con halogeno, hidroxi, nitro, S(O)ralquiloC1-4, S(O)2NH2, S(O)2NHalquiloC1-4, S(O)2N(alquilo C1- 4)2, ciano, alquilo C1-4, alcoxi C1-4, C(O)NH2, C(O)NHalquiloC1-4, C(O)N(alquilo C1-4)2, CO2H, CO2alquiloC1-4, NHC(O)alquiloC1-4, NHS(O)2alquiloC1-4, C(O)alquiloC1-4, CF3 o OCF3; A1, E1 y G1 son, en forma independiente, hidrogeno, halogeno, ciano, hidroxi, alquilo C1-4, alcoxi C1-4, CF3 o OCF3; q y r son, en forma independiente, 0, 1 o 2; R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22 y R23 son, en forma independiente, alquilo C1-6 {opcionalmente sustituido por halogeno, hidroxi o alcoxi C1-6}, CH2alqueniloC2-6, fenilo {en sí opcionalmente sustituido por halogeno, hidroxi, nitro, NH2, NHalquiloC1-4, N(alquilo C1-4)2, S(O)2alquiloC1-4, S(O)2NH2, S(O)2NHalquiloC1-4, S(O)2N(alquilo C1-4)2, ciano, alquilo C1-4, alcoxi C1-4, C(O)NH2, C(O)NHalquiloC1-4, C(O)N(alquilo C1-4)2, CO2H, CO2alquiloC1-4, NHC(O)alquiloC1-4, NHS(O)2alquilo C1-4, C(O)alquiloC1-4, CF3 o OCF3} o heteroarilo {en sí opcionalmente sustituido por halogeno, hidroxi, nitro, NH2, NHalquiloC1-4, N(alquilo C1-4)2, S(O)2alquiloC1-4, S(O)2NH2, S(O)2NHalquiloC1-4, S(O)2N(alquilo C1-4)2, ciano, alquilo C1-4, alcoxi C1-4, C(O)NH2, C(O)NHalquiloC1-4, C(O)N(alquilo C1-4)2, CO2H, CO2alquiloC1-4, NHC(O)alquiloC1-4, NHS(O)2alquiloC1-4, C(O)alquiloC1-4, CF3 O OCF3}; R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R18, R19, R20, R21, R22 y R23 también pueden ser hidrogeno; o un N-oxido del mismo, o una sal aceptable para uso farmacéutico del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0501564 | 2005-07-04 | ||
| SE0600516 | 2006-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057433A1 true AR057433A1 (es) | 2007-12-05 |
Family
ID=37604725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102882A AR057433A1 (es) | 2005-07-04 | 2006-07-04 | Compuestos quimicos derivados de piridopirimidina, un metodo para su preparacion y composicion farmaceutica |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080227797A1 (es) |
| EP (1) | EP1922318A1 (es) |
| JP (1) | JP2009500405A (es) |
| AR (1) | AR057433A1 (es) |
| TW (1) | TW200726767A (es) |
| UY (1) | UY29648A1 (es) |
| WO (1) | WO2007004958A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200800997A (en) * | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
| WO2008084236A1 (en) * | 2007-01-11 | 2008-07-17 | Astrazeneca Ab | Chemical compounds 635 : pyridopyrimidinediones as pde4 inhibitors |
| SA08280783B1 (ar) * | 2007-01-11 | 2011-04-24 | استرازينيكا ايه بي | مشتقات بيريدوبيريميدين كمثبطات pde4 |
| TW200835497A (en) * | 2007-01-11 | 2008-09-01 | Astrazeneca Ab | Chemical compounds 636 |
| WO2008142623A2 (en) * | 2007-05-17 | 2008-11-27 | Piramal Life Sciences Limited | Tumor necrosis factor - alpha inhibitors |
| AU2009206368B2 (en) | 2008-01-25 | 2014-12-11 | Vtv Therapeutics Llc | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors |
| CL2009000904A1 (es) * | 2008-04-21 | 2010-04-30 | Shionogi & Co | Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende. |
| WO2010004319A1 (en) * | 2008-07-07 | 2010-01-14 | Astrazeneca Ab | Combination comprising 6-flu0r0-n- ((1s, 4s) - 4- (6-fluoro-2, 4-di0x0-1- (4'- (piperazin-1- ylmethyl) biphenyl- 3-yl) -1, 2-dihydropyrido [2, 3-d] pyrimidin-3 (4h) - yl) cyclohexyl) imidazo [1,2-a] pyridine -2- carboxamide or a salt |
| BR112016007078A2 (pt) | 2013-09-30 | 2017-12-12 | Ono Pharmaceutical Co | composto tendo atividade agonística do receptor de somatostatina e uso farmacêutico do mesmo |
| AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| US11174256B2 (en) | 2018-10-30 | 2021-11-16 | Gilead Sciences, Inc. | Imidazopyridine derivatives |
| HRP20250191T1 (hr) | 2018-10-30 | 2025-04-11 | Gilead Sciences, Inc. | Derivati 3-(kinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-diona kao inhibitori alfa4beta7 integrina za liječenje upalnih bolesti |
| JP7189369B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４β７インテグリンの阻害のための化合物 |
| EP4013499A1 (en) | 2019-08-14 | 2022-06-22 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| NZ790364A (en) * | 2020-01-29 | 2025-12-19 | Kamari Pharma Ltd | Compounds and compositions for use in treating skin disorders |
| CN111808098B (zh) * | 2020-06-29 | 2021-08-24 | Vtv治疗有限责任公司 | 喹啉衍生物，其药学上可接受的盐及其使用方法 |
| JPWO2023042879A1 (es) * | 2021-09-17 | 2023-03-23 | ||
| WO2023175185A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE63553T1 (de) * | 1986-08-21 | 1991-06-15 | Pfizer | Chinazolindione und pyridopyrimidindione. |
| US5264437A (en) * | 1992-03-20 | 1993-11-23 | Syntex (U.S.A.) Inc. | Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones |
| AU9002598A (en) * | 1997-09-16 | 1999-04-05 | Takeda Chemical Industries Ltd. | Nitrogenous fused-ring compounds, process for the preparation of the same, and drugs |
| AR029185A1 (es) * | 1999-10-25 | 2003-06-18 | Yamanouchi Pharma Co Ltd | Derivado de naftiridina |
| WO2003089416A1 (de) * | 2002-04-22 | 2003-10-30 | Ibfb Gmbh | Substituierte pyrimidin-2,4(1h,3h)-dione als matrix metalloproteinase (mmp) inhibitoren |
| GB0217225D0 (en) * | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| SA08280783B1 (ar) * | 2007-01-11 | 2011-04-24 | استرازينيكا ايه بي | مشتقات بيريدوبيريميدين كمثبطات pde4 |
| UA100979C2 (ru) * | 2007-04-10 | 2013-02-25 | Экселиксис, Инк. | Применение пиридопиримидиноновых ингибиторов pi3k альфа для лечения рака |
-
2006
- 2006-06-23 TW TW095122695A patent/TW200726767A/zh unknown
- 2006-07-03 UY UY29648A patent/UY29648A1/es not_active Application Discontinuation
- 2006-07-03 US US11/994,572 patent/US20080227797A1/en not_active Abandoned
- 2006-07-03 JP JP2008520211A patent/JP2009500405A/ja active Pending
- 2006-07-03 EP EP06758019A patent/EP1922318A1/en not_active Withdrawn
- 2006-07-03 WO PCT/SE2006/000826 patent/WO2007004958A1/en not_active Ceased
- 2006-07-04 AR ARP060102882A patent/AR057433A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200726767A (en) | 2007-07-16 |
| EP1922318A1 (en) | 2008-05-21 |
| US20080227797A1 (en) | 2008-09-18 |
| WO2007004958A1 (en) | 2007-01-11 |
| UY29648A1 (es) | 2007-02-28 |
| JP2009500405A (ja) | 2009-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057433A1 (es) | Compuestos quimicos derivados de piridopirimidina, un metodo para su preparacion y composicion farmaceutica | |
| AR060046A1 (es) | Derivados de 2, 4-dioxo-1, 4-dihidropirido[2, 3 -d]pirimidina, un proceso para prepararlos e intermediario para su sintesis, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por pde4 | |
| PE20140609A1 (es) | Diazacarbazoles y metodos de uso | |
| AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
| PE20070189A1 (es) | COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| AR059516A1 (es) | Derivados de isoxazolina, procesos de obtencion y composiciones herbicidas | |
| PE20091694A1 (es) | DERIVADOS POLISUSTITUIDOS DE 6-HETEROARIL-IMIDAZO[1,2-a] PIRIDINAS COMO MODULADORES DE LOS RECEPTORES NOT Y SU PREPARACION | |
| CY1113687T1 (el) | Παραγωγα αμινο νικοτινικου και ισο-νικοτινικου οξεος σαν παραγοντες καταστολης της dhodh | |
| PE20100138A1 (es) | Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k | |
| AR066155A1 (es) | Compuestos de pirazol, simil tiroideo, composicion farmaceutica, proceso y uso en terapia | |
| PE20050691A1 (es) | Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la cinasa | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| CO6270320A2 (es) | Derivados de piperidina utiles como antagonistas del receptor orexina | |
| CY1107008T1 (el) | Παραγωγο βενζιμιδαζολης και χρηση ως ανταγωνιστου υποδοχεα aii | |
| AR059338A1 (es) | N-fenilbenzotriazolilo como inhibidores de c-kit | |
| AR065280A1 (es) | Agentes antiparasitarios | |
| PE20130012A1 (es) | Derivados de pirazol como inhibidores de jak | |
| PE20091957A1 (es) | Compuestos triazina como inhibidores mtor y quinasa pi3 | |
| ATE388146T1 (de) | 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor | |
| PE20080277A1 (es) | Derivados de azaindol espirociclicos y sustituidos | |
| AR070485A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
| CO6140030A2 (es) | Derivados de 4-bencilftalazinona 2-sustituidos como antagonistas de histamina h1 y h3 | |
| AR065863A1 (es) | Derivados de imidazolidinona | |
| PE20081665A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |